Literature DB >> 17103304

Fluoxetine monotherapy in attention-deficit/hyperactivity disorder and comorbid non-bipolar mood disorders in children and adolescents.

Humberto Quintana1, Grant J Butterbaugh, William Purnell, Ann K Layman.   

Abstract

Children with attention-deficit/hyperactivity disorder (ADHD) are at increased risk for developing comorbid non-bipolar mood disorders. Fluoxetine monotherapy is an established treatment for pediatric mood disorders; however its efficacy in ADHD and comorbid mood disorder is unknown. Therefore, we evaluated 30 children who met DSM-IV criteria for ADHD and comorbid non-bipolar mood disorders in a prospective, 6-12-week open-label, study of fluoxetine monotherapy. Fluoxetine was associated with significant decreases in the severity of depressive symptoms, and also, associated with significant decreases on subscales of inattention/overactivity and aggression/defiant symptoms-47% of participants were much or very much improved without observed adverse effects.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17103304     DOI： 10.1007/s10578-006-0032-7

Source DB:  PubMed          Journal:  Child Psychiatry Hum Dev        ISSN： 0009-398X


  20 in total

1.  Tricyclic antidepressants in the treatment of children with attention deficit disorder.

Authors:  S R Pliszka
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1987-03       Impact factor: 8.829

2.  Study I: development and criterion validity of the Children's Interview for Psychiatric Syndromes (ChIPS).

Authors:  M Teare; M A Fristad; E B Weller; R A Weller; P Salmon
Journal:  J Child Adolesc Psychopharmacol       Date:  1998       Impact factor: 2.576

3.  Open-label treatment of comorbid depression and attentional disorders with co-administration of serotonin reuptake inhibitors and psychostimulants in children, adolescents, and adults: a case series.

Authors:  R L Findling
Journal:  J Child Adolesc Psychopharmacol       Date:  1996       Impact factor: 2.576

Review 4.  Review of the efficacy and safety of antidepressants in youth depression.

Authors:  Amy H Cheung; Graham J Emslie; Taryn L Mayes
Journal:  J Child Psychol Psychiatry       Date:  2005-07       Impact factor: 8.982

5.  Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.

Authors:  John March; Susan Silva; Stephen Petrycki; John Curry; Karen Wells; John Fairbank; Barbara Burns; Marisa Domino; Steven McNulty; Benedetto Vitiello; Joanne Severe
Journal:  JAMA       Date:  2004-08-18       Impact factor: 56.272

6.  Treatment of ADHD with fluoxetine: a preliminary trial.

Authors:  L Barrickman; R Noyes; S Kuperman; E Schumacher; M Verda
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1991-09       Impact factor: 8.829

7.  Fluoxetine-induced memory impairment in an adolescent.

Authors:  M E Bangs; T A Petti; M D Janus
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1994 Nov-Dec       Impact factor: 8.829

8.  Efficacy of tricyclic drugs in treating child and adolescent depression: a meta-analysis.

Authors:  P Hazell; D O'Connell; D Heathcote; J Robertson; D Henry
Journal:  BMJ       Date:  1995-04-08

9.  A children's global assessment scale (CGAS).

Authors:  D Shaffer; M S Gould; J Brasic; P Ambrosini; P Fisher; H Bird; S Aluwahlia
Journal:  Arch Gen Psychiatry       Date:  1983-11

Review 10.  Newer antidepressants and the cytochrome P450 system.

Authors:  C B Nemeroff; C L DeVane; B G Pollock
Journal:  Am J Psychiatry       Date:  1996-03       Impact factor: 18.112
View more
  11 in total

1.  Bone growth in juvenile rhesus monkeys is influenced by 5HTTLPR polymorphisms and interactions between 5HTTLPR polymorphisms and fluoxetine.

Authors:  Mari S Golub; Alicia M Bulleri; Casey E Hogrefe; Richard J Sherwood
Journal:  Bone       Date:  2015-06-09       Impact factor: 4.398

2.  Peripheral fibroblast metabolic pathway alterations in juvenile rhesus monkeys undergoing long-term fluoxetine administration.

Authors:  Shu-Yi Su; Casey E Hogrefe-Phi; John M Asara; Christoph W Turck; Mari S Golub
Journal:  Eur Neuropsychopharmacol       Date:  2016-04-12       Impact factor: 4.600

3.  Impact of treatments for depression on comorbid anxiety, attentional, and behavioral symptoms in adolescents with selective serotonin reuptake inhibitor-resistant depression.

Authors:  Robert C Hilton; Manivel Rengasamy; Brandon Mansoor; Jiayan He; Taryn Mayes; Graham J Emslie; Giovanna Porta; Greg N Clarke; Karen Dineen Wagner; Boris Birmaher; Martin B Keller; Neal Ryan; Wael Shamseddeen; Joan Rosenbaum Asarnow; David A Brent
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2013-04-04       Impact factor: 8.829

4.  Altered interregional molecular associations of the serotonin transporter in attention deficit/hyperactivity disorder assessed with PET.

Authors:  Thomas Vanicek; Alexandra Kutzelnigg; Cecile Philippe; Helen L Sigurdardottir; Gregory M James; Andreas Hahn; Georg S Kranz; Anna Höflich; Alexander Kautzky; Tatjana Traub-Weidinger; Marcus Hacker; Wolfgang Wadsak; Markus Mitterhauser; Siegfried Kasper; Rupert Lanzenberger
Journal:  Hum Brain Mapp       Date:  2016-10-22       Impact factor: 5.038

5.  Validation of a Brief Structured Interview: The Children's Interview for Psychiatric Syndromes (ChIPS).

Authors:  Matthew E Young; Ziv E Bell; Mary A Fristad
Journal:  J Clin Psychol Med Settings       Date:  2016-12

6.  Treatment response in depressed adolescents with and without co-morbid attention-deficit/hyperactivity disorder in the Treatment for Adolescents with Depression Study.

Authors:  Christopher J Kratochvil; Diane E May; Susan G Silva; Vishal Madaan; Susan E Puumala; John F Curry; John Walkup; Hayden Kepley; Benedetto Vitiello; John S March
Journal:  J Child Adolesc Psychopharmacol       Date:  2009-10       Impact factor: 2.576

7.  Inverse fluoxetine effects on inhibitory brain activation in non-comorbid boys with ADHD and with ASD.

Authors:  Kaylita Chantiluke; Nadia Barrett; Vincent Giampietro; Paramala Santosh; Michael Brammer; Andrew Simmons; Declan G Murphy; Katya Rubia
Journal:  Psychopharmacology (Berl)       Date:  2014-12-24       Impact factor: 4.530

8.  Inverse Effect of Fluoxetine on Medial Prefrontal Cortex Activation During Reward Reversal in ADHD and Autism.

Authors:  Kaylita Chantiluke; Nadia Barrett; Vincent Giampietro; Michael Brammer; Andrew Simmons; Declan G Murphy; Katya Rubia
Journal:  Cereb Cortex       Date:  2014-01-22       Impact factor: 5.357

9.  Cognitive performance of juvenile monkeys after chronic fluoxetine treatment.

Authors:  Mari S Golub; Edward P Hackett; Casey E Hogrefe; Csaba Leranth; John D Elsworth; Robert H Roth
Journal:  Dev Cogn Neurosci       Date:  2017-05-01       Impact factor: 6.464

10.  Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis.

Authors:  Jackie Y W Cheng; Ronald Y L Chen; John S N Ko; Emil M L Ng
Journal:  Psychopharmacology (Berl)       Date:  2007-06-16       Impact factor: 4.415
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.